- Home
- ASC vs ATXS Comparison
ASC vs ATXS Comparison
Compare ASC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- ATXS
- Stock Information
- Founded
- ASC 2010
- ATXS 2008
- Country
- ASC Bermuda
- ATXS United States
- Employees
- ASC N/A
- ATXS N/A
- Industry
- ASC Marine Transportation
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- ATXS Health Care
- Exchange
- ASC Nasdaq
- ATXS Nasdaq
- Market Cap
- ASC 399.7M
- ATXS 401.2M
- IPO Year
- ASC 2013
- ATXS 2015
- Fundamental
- Price
- ASC $10.22
- ATXS $6.65
- Analyst Decision
- ASC Buy
- ATXS Strong Buy
- Analyst Count
- ASC 3
- ATXS 7
- Target Price
- ASC $13.67
- ATXS $32.43
- AVG Volume (30 Days)
- ASC 555.9K
- ATXS 304.1K
- Earning Date
- ASC 07-30-2025
- ATXS 08-11-2025
- Dividend Yield
- ASC 9.30%
- ATXS N/A
- EPS Growth
- ASC N/A
- ATXS N/A
- EPS
- ASC 2.30
- ATXS N/A
- Revenue
- ASC $373,479,000.00
- ATXS N/A
- Revenue This Year
- ASC N/A
- ATXS N/A
- Revenue Next Year
- ASC N/A
- ATXS N/A
- P/E Ratio
- ASC $4.49
- ATXS N/A
- Revenue Growth
- ASC N/A
- ATXS N/A
- 52 Week Low
- ASC $8.32
- ATXS $3.56
- 52 Week High
- ASC $22.70
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- ASC 53.07
- ATXS 60.88
- Support Level
- ASC $9.90
- ATXS $5.94
- Resistance Level
- ASC $10.53
- ATXS $6.49
- Average True Range (ATR)
- ASC 0.30
- ATXS 0.34
- MACD
- ASC 0.01
- ATXS -0.00
- Stochastic Oscillator
- ASC 54.55
- ATXS 74.74
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.